文献速递头颈外科

抑郁症遗传风险与头颈癌患者的生活质量

Genetic Risk For Depression and Quality of Life in Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项前瞻性纵向研究纳入223例新诊断头颈癌患者,评估诊断时因素与治疗3个月后生活质量的关系。发现较高的抑郁症多基因风险评分、诊断2周内重性抑郁障碍、终生自杀意念、过去30天吸烟、化疗类型及放疗总剂量与3个月生活质量较低相关,而与他人同住与生活质量较高相关。

要点

  • 较高的抑郁症多基因风险评分与治疗3个月后生活质量较低相关(B=-4.71)。
  • 诊断2周内重性抑郁障碍与3个月生活质量较低相关(B=-32.24)。
  • 与他人同住与3个月生活质量较高相关(B=12.48)。

核心结论

  • 抑郁症遗传易感性对肿瘤治疗后即刻生活质量和功能具有预测价值。
  • 这些发现提示治疗前基因分型可能有助于识别易出现生活质量和功能受损的患者。
  • 抑郁是明确的公共卫生问题,应成为头颈癌患者治疗的核心关注点。

研究设计与样本

  • 前瞻性纵向研究,纳入1464例符合条件的参与者,223例(72%)同意参与并完成基线问卷,71%完成3个月随访评估。
  • 研究在麦吉尔大学附属2家三级医院(麦吉尔大学健康中心和犹太总医院)耳鼻咽喉头颈外科进行。
  • 纳入标准:新诊断2周内原发性首次头颈癌成人,卡氏功能状态评分高于60,预期生存超过6个月。
  • 暴露因素包括社会人口学、医学变量、心理社会危险因素和抑郁症多基因风险评分(PRS-D)。
  • 主要结局用癌症治疗功能评估-头颈量表在基线和3个月时测量生活质量。

主要发现

  • 参与者多数为男性(68.7%),平均(范围)年龄62.9(31-92)岁,36.6%有大学学位,35.6%独居,71.4%诊断为晚期头颈癌,最常见为口咽癌(42.2%)、口腔癌(17%)和喉癌(16.3%)。
  • 头颈癌诊断后3个月生活质量与较高PRS-D相关(B=-4.71;95%CI,-9.18至-0.23)。
  • 与头颈癌诊断2周内重性抑郁障碍诊断相关(B=-32.24;95%CI,-51.47至13.02)。
  • 与终生自杀意念相关(B=-22.39;95%CI,-36.14至-8.65)。
  • 与头颈癌诊断前30天内吸烟相关(B=-15.50;95%CI,-26.07至-4.93),与化疗类型相关(B=-11.13;95%CI,-21.23至-1.02),与放疗总剂量(Gy)相关(B=-0.008;95%CI,-0.01至-0.002);与他人同住与生活质量较高相关(B=12.48;95%CI,3.43-21.52)。

临床怎么用

  • 作者认为这些发现凸显了治疗前基因分型识别易出现生活质量和功能受损患者的潜在重要性。
  • 作者指出抑郁是明确的公共卫生问题,应成为头颈癌患者治疗的核心关注点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although patients with head and neck cancer (HNC) have been shown to experience high distress, few longitudinal studies include a comprehensive evaluation of biopsychosocial factors affecting quality of life (QoL), including genetic risk for depression. OBJECTIVE: To identify factors at the time of cancer diagnosis associated with QoL scores at 3 months after treatment in patients newly diagnosed with a first occurrence of HNC. DESIGN, SETTING, AND PARTICIPANTS: This prospective longitudinal study of 1464 participants with a 3-month follow-up, including structured clinical interviews and self-administered measures was carried out at the Department of Otolaryngology Head and Neck Surgery at 2 tertiary care McGill University Affiliated Hospitals, McGill University Health Centre, and Jewish General Hospital. Eligible patients were adults newly diagnosed within 2 weeks with a primary first occurrence of HNC, had a Karnofsky Performance Scale score higher than 60, and an expected survival of more than 6 months. Two hundred and twenty-three patients (72%) consented to participate and completed the baseline questionnaire, and 71% completed the 3-month follow-up measures. EXPOSURES: An a priori conceptual model including sociodemographics, medical variables, psychosocial risk factors, and a polygenic risk score for depression (PRS-D) was tested. MAIN OUTCOMES AND MEASURES: The Functional Assessment of Cancer Therapy-Head and Neck measured QoL at baseline and at 3 months. RESULTS: Participants were mostly men (68.7%), with a mean (range) age of 62.9 (31-92) years, 36.6% having a university degree, 35.6% living alone, and 71.4% diagnosed with advanced HNC with mostly cancers being of the oropharynx (42.2%), oral cavity (17%), and larynx (16.3%). QoL at 3 months after HNC diagnosis was associated with higher PRS-D (B = -4.71; 95% CI, -9.18 to -0.23), and a diagnosis of major depressive disorder within 2 weeks of an HNC diagnosis (B = -32.24; 95% CI, -51.47 to 13.02), lifetime suicidal ideation (B = -22.39; 95% CI, -36.14 to -8.65), living with someone (B = 12.48; 95% CI, 3.43-21.52), having smoked cigarettes in the past 30 days pre-HNC diagnosis (B = -15.50; 95% CI, -26.07 to -4.93), chemotherapy type (B = -11.13; 95% CI, -21.23 to -1.02), and total radiotherapy dose (Gy) (B = -0.008; 95% CI, -0.01 to -0.002). CONCLUSIONS AND RELEVANCE: This study identified the predictive value of a genetic predisposition to depression on QoL and function immediately after oncologic treatments. These findings highlight the potential importance of genetic profiling pretreatment to identify those most susceptible to experience QoL and functional compromise. Depression is a clear area of public health concern and should be a central focus in the treatment of patients with HNC.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Henry M, Chen LM, Ducharme L, et al. Genetic Risk For Depression and Quality of Life in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38814668. doi:10.1001/jamaoto.2024.0376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。